Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.

Journal Article (Journal Article;Review)

Targeted therapies have transformed the treatment paradigm in diseases such as non-small cell lung cancer and melanoma but have shown relatively modest clinical benefit in gastrointestinal malignancies. Anti-EGFR therapy in RAS wild-type colorectal cancer, anti-HER2 therapy in HER2- amplified esophagogastric cancer, and FGFR and isocitrate dehydrogenase 1 (IDH1) inhibitors in FGFR2 fusion-positive and IDH1-mutant biliary tract cancers offer antitumor efficacy, but the clinical benefit and durability of response in each case are typically limited. We review targeted therapies in each of these therapeutic areas and discuss their clinical efficacy, mechanisms of primary and acquired resistance, and strategies to overcome this resistance. We discuss lessons learned that we hope will lead to an expanded role for molecularly targeted therapy options for patients with gastrointestinal cancers.

Full Text

Duke Authors

Cited Authors

  • Chen, C; Di Bartolomeo, M; Corallo, S; Strickler, JH; Goyal, L

Published Date

  • May 2020

Published In

Volume / Issue

  • 40 /

Start / End Page

  • 161 - 173

PubMed ID

  • 32421451

Electronic International Standard Serial Number (EISSN)

  • 1548-8756

Digital Object Identifier (DOI)

  • 10.1200/EDBK_280871


  • eng

Conference Location

  • United States